Objective To explore the effects of Runpo Decoction combined with Bifidobacterium Triple Viable Capsules on anorectal dynamics and intestinal flora levels in elderly patients with diabetic constipation. Methods From January 2021 to January 2024, 122 elderly patients with diabetic constipation treated at Nuclear Industry 215 Hospital of Shaanxi Province were selected for the randomized controlled trial, and were divided into a control group and a combined group by the random number table method, with 61 cases in each group. There were 16 males and 45 females in the control group; they were (64.83±9.97) years old; their diabetic course was (7.49±2.31) years; the constipation course was (1.40±0.61) years. There were 19 males and 42 females in the combined group; they were (65.18±10.16) years old; their diabetic course was (7.36±2.27) years; the constipation course was (1.37±0.52) years. Both groups took Bifidobacterium Triple Viable Capsules; in addition, the combined group took Runpo Decoction. The symptoms of defecation, intestinal flora levels, anorectal dynamics, and quality of life before and 2 weeks after the treatment and incidences of adverse reactions were compared between the groups using t and χ2 tests. Results Before the treatment, there were no statistical differences in symptoms of defecation, intestinal flora levels, anorectal dynamics, and quality of life between the two groups. After the treatment, the defecation frequency, counts of lactobacillus and bifidobacterium, and rectal evacuation pressure in the combined group were higher than those in the control group [(6.93±1.18) times/week vs. (5.15±1.07) times/week, (7.04±0.61) IgCFU/g vs. (6.18±0.67) IgCFU/g, (8.73±0.79) IgCFU/g vs. (7.45±0.80) IgCFU/g, and (54.69±3.86) mmHg(1 mmHg=0.133 kPa) vs. (41.63±1.72) mmHg]; the defecation time in the combined group was shorter than that in the combined group [(7.75±1.64) min/time vs. (10.89±1.58) min/time]; the count of Escherichia coli, residual anal pressure, rectal evacuation threshold, initial rectal sensation threshold, and scores of physical discomfort, psychosocial discomfort, anxiety concerns, and satisfaction in the combined group were lower than those in the control group [(5.28±0.39) IgCFU/g vs. (6.40±0.48) IgCFU/g, (46.92±3.37) mmHg vs. (62.08±3.98) mmHg, (160.18±3.85) ml vs. (165.07±4.01) ml, (40.93±2.97) ml vs. (46.93±3.14) ml, (3.98±1.17) vs. (5.17±1.08), (11.64±1.75) vs. (15.75±2.06), (14.56±2.95) vs. (23.78±2.86), and (5.34±1.97) vs. (8.15±2.18)]; there were statistical differences (t=8.728, 7.413, 8.892, 24.137, 10.769, 14.144, 22.704, 6.870, 10.842, 5.837, 11.876, 17.526, and 7.469; all P<0.05). There was no statistical difference in the incidence of adverse reactions between the two groups (χ2=0.209,P=0.648). Conclusion Runpo decoction combined with Bifidobacterium Triple Viable Capsules for elderly patients with diabetic constipation can significantly improve their anorectal dynamics and intestinal flora levels, promote their restoration of intestinal function, and is safe, so it is worth being clinically generalized.